Short-term use of the BEZ/GSK/TSA drug combination (hereafter referred to as BGT) caused growth inhibition and cell death of up to 90% of KRAS mutant cancer cells (Supplementary Figure 1A, 1B). This evidence concerns the gene KRAS and cancer.